It is estimated that 115 million people globally will have Alzheimer’s disease by 2050. In the US alone, a cost of $1,000bn is predicted. Disease-modifying therapies that delay the onset of AD or slow its progression are a major unmet medical need.
Advances in Alzheimer’s Disease Drug Discovery eBook Free
